Skip to content
MARKETS / BALCAO / CBDY
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

Target Group Inc. CBDY

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$3.9M
▼ 41.1% YoY
$-1.4M
▼ 947.1% YoY
In brief

What this company does

Effective July 1, 2025, the Company’s common stock is quoted on the Pink Limited Market operated by OTC Markets Group Inc, under the symbol “CBDY”. The Company is engaged in the cultivation, processing and distribution of curated cannabis products for the medical and adult-use recreational cannabis market in Canada and continues to evaluate opportunities, where legalized by state legislation or related to rescheduling, in the United States. As of the date of this report, the Company and its subsidiaries do not have any operations, employees or corporate offices based in United States. Visava owns 100% of Canary Rx Inc, a Canadian corporation (“Canary”) that operates a 44,000 square foot facility located in Ontario’s Garden Norfolk County for the production of cannabis.

Written from the business description in Target Group Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 3.9M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 3.9 · Net income -1.4
2.5M5.0M-4.0M-8.0M2014201620182020202220242025
Compound annual growth
+164.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +164.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−35 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -35.0% · Net -35.0%
-200000%-400000%-600000%2014201620182020202220242025
ROE
FY2020 · ROE -5282.9%
-2000%-4000%2014201620182020202220242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2020 · FCF -1.5
-4M-8M2014201620182020202220242025
Net buybacks $ Dividends $
FY2015 · Dividends — · Net buybacks -12500.0
-5000-1000020142015

Total assetsUSD 6.2M
EquityUSD -8.1M
CashUSD 108,800.00
Gross debtUSD 15.2M
Net debtUSD 15.1M
Current ratio0.17×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.00.00.00.00.00.0·
Operating income $B−0.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.00.00.0−0.00.0−0.0−0.0−0.0····
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.0
Net income $B−0.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B·····−0.0−0.0·····
EPS, diluted $−0.000.00−0.00−0.010.00−0.01−0.03−0.04−0.72−85.83−0.34−0.03
Dividend / sh $············
Payout %············
ROE %·····−5282.9−290.7−296.5····
Shares out B0.620.620.620.620.620.570.570.090.010.000.020.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 54 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 41 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image